Eupraxia Pharmaceuticals Inc (EPRX) Stock Price, Quote & News

Company Profile

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial...

Industry: Biotechnology

Sector: Healthcare

Phone: 250-590-3968

Website: www.eupraxiapharma.com

Address:

2067 Cadboro Bay Road, Suite 201, Victoria, Canada

Moneybags789 Jun. 30 at 2:05 PM

$EPRX compared to normal daily volume today is incredible. Is she getting ready to make monumental moves?

0 · Reply

AlertsAndNews Jun. 30 at 2:43 AM

Happy Sunday, updated gappers from Friday $VERO $GDHG $PLRX $YJ $EPRX Full watchlist out for the team, looking forward to a great week. Let's see what happened out here this weekend.

0 · Reply

jheerdink Jun. 29 at 5:13 PM

$EPRX Is this 1-year chart for $EPRX Eupraxia the beginning of a #BreakoutStock ? #biotech #trading #investing #stocks #insiderbuying #lowfloat #equities #StocksToWatch

1 · Reply

jheerdink Jun. 27 at 8:11 PM

$EPRX $5.30 close another new high.....

1 · Reply

jheerdink Jun. 27 at 5:40 PM

$EPRX $5.19 tight float melting up hitting new highs?

0 · Reply

Doozio Jun. 27 at 5:04 PM

$EPRX 🐒🍌🧠⏰♾️ n $XBI YO next!

0 · Reply

jheerdink Jun. 26 at 3:50 PM

$EPRX new YTD High at $4.50 today!

1 · Reply

JarvisFlow Jun. 26 at 12:00 PM

HC Wainwright & Co. has updated their rating for Eupraxia Pharmaceuticals ( $EPRX ) to Buy with a price target of 12.

0 · Reply

jheerdink Jun. 25 at 6:50 PM

$EPRX Check out their 1-year chart as of this time! https://finance.yahoo.com/quote/EPRX/

0 · Reply

Moneybags789 Jun. 25 at 5:53 PM

$EPRX new 52 week I!!

0 · Reply

Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders

May 7, 2025, 2:00 PM EDT - 7 weeks ago

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025

May 6, 2025, 6:00 PM EDT - 7 weeks ago

Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

Apr 24, 2025, 5:00 PM EDT - 2 months ago

Eupraxia Pharmaceuticals to Present at Investor and Scientific Conferences in April and May

Mar 20, 2025, 5:31 PM EDT - 3 months ago

Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Feb 25, 2025, 7:00 AM EST - 4 months ago

Eupraxia Pharmaceuticals Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Feb 18, 2025, 7:00 AM EST - 4 months ago

Eupraxia Pharmaceuticals Announces CFO Succession

Nov 20, 2024, 7:00 AM EST - 7 months ago

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Nov 14, 2024, 5:00 PM EST - 8 months ago

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Nov 13, 2024, 5:00 PM EST - 8 months ago

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Nov 12, 2024, 5:56 PM EST - 8 months ago

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Nov 7, 2024, 5:00 PM EST - 8 months ago

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Oct 31, 2024, 7:36 PM EDT - 8 months ago

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

Oct 28, 2024, 7:00 AM EDT - 8 months ago

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

Oct 15, 2024, 7:00 AM EDT - 9 months ago

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

Oct 10, 2024, 7:00 AM EDT - 9 months ago

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

Oct 2, 2024, 5:01 PM EDT - 9 months ago

Eupraxia Pharmaceuticals Strengthens Senior Management Team

Sep 19, 2024, 5:00 PM EDT - 10 months ago

Eupraxia Pharmaceuticals to Present at 20th ISDE World Congress for Esophageal Diseases

Sep 11, 2024, 7:00 AM EDT - 10 months ago

Eupraxia Pharmaceuticals Announces Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Sep 4, 2024, 7:00 AM EDT - 10 months ago

Eupraxia Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 7, 2024, 5:00 PM EDT - 11 months ago

Eupraxia Pharmaceuticals Reports Second Quarter 2024 Financial Results

Aug 2, 2024, 7:00 AM EDT - 11 months ago

Eupraxia Pharmaceuticals Announces New C$12 Million Convertible Debt Facility

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo

Jul 3, 2024, 5:00 PM EDT - 1 year ago

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024

Jun 5, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024

May 23, 2024, 5:00 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

May 22, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024

May 21, 2024, 5:00 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

May 14, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024

May 8, 2024, 5:03 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals Announces Upcoming Presentations at the Osteoarthritis Research Society International World Congress 2024

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals To Present at Bloom Burton & Co. Healthcare Investor Conference

Apr 5, 2024, 7:00 AM EDT - 1 year ago

Eupraxia Pharmaceuticals Begins Trading on Nasdaq Today

Apr 3, 2024, 5:00 PM EDT - 1 year ago

Eupraxia Pharmaceuticals to Begin Trading on Nasdaq on April 5, 2024

Apr 1, 2024, 5:01 PM EDT - 1 year ago

Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results

Moneybags789 Jun. 30 at 2:05 PM

$EPRX compared to normal daily volume today is incredible. Is she getting ready to make monumental moves?

0 · Reply

AlertsAndNews Jun. 30 at 2:43 AM

Happy Sunday, updated gappers from Friday $VERO $GDHG $PLRX $YJ $EPRX Full watchlist out for the team, looking forward to a great week. Let's see what happened out here this weekend.

0 · Reply

jheerdink Jun. 29 at 5:13 PM

$EPRX Is this 1-year chart for $EPRX Eupraxia the beginning of a #BreakoutStock ? #biotech #trading #investing #stocks #insiderbuying #lowfloat #equities #StocksToWatch

1 · Reply

jheerdink Jun. 27 at 8:11 PM

$EPRX $5.30 close another new high.....

1 · Reply

jheerdink Jun. 27 at 5:40 PM

$EPRX $5.19 tight float melting up hitting new highs?

0 · Reply

Doozio Jun. 27 at 5:04 PM

$EPRX 🐒🍌🧠⏰♾️ n $XBI YO next!

0 · Reply

jheerdink Jun. 26 at 3:50 PM

$EPRX new YTD High at $4.50 today!

1 · Reply

JarvisFlow Jun. 26 at 12:00 PM

HC Wainwright & Co. has updated their rating for Eupraxia Pharmaceuticals ( $EPRX ) to Buy with a price target of 12.

0 · Reply

jheerdink Jun. 25 at 6:50 PM

$EPRX Check out their 1-year chart as of this time! https://finance.yahoo.com/quote/EPRX/

0 · Reply

Moneybags789 Jun. 25 at 5:53 PM

$EPRX new 52 week I!!

0 · Reply

Moneybags789 Jun. 18 at 2:30 PM

$EPRX approaching new 52 week high!!

0 · Reply

Trex28 Jun. 18 at 2:17 AM

$EPRX Not a ton of folks here, but the company is solid. I added to my small position here today after some BIG gains from PCSA.

0 · Reply

Moneybags789 Jun. 16 at 7:43 PM

$EPRX 👀👀👀👀

0 · Reply

jheerdink Jun. 10 at 1:03 AM

$EPRX

0 · Reply

Doozio Jun. 3 at 12:35 AM

$EPRX thin to win as da 🧠 spreads in HRMY as $XBI gets in RYTM during 🐒🍌🧠⏰♾️

0 · Reply

jheerdink May. 22 at 6:07 PM

$EPRX World Eosinophilic Esophagitis Day: Shining a Spotlight on EoE and Hope for the Future https://vistapglobal.com/world-eosinophilic-esophagitis-day-shining-a-spotlight-on-eoe-and-hope-for-the-future-eprx/

0 · Reply

jheerdink May. 19 at 5:56 PM

$EPRX "We recently achieved a significant clinical milestone with the release of positive nine-month data from our ongoing open-label, dose-escalation Phase 1b/2a RESOLVE trial, which continue to support EP-104GI as a potentially transformative therapy for eosinophilic esophagitis,” said Dr. James Helliwell, Chief Executive Officer of Eupraxia. “The sustained or improved treatment outcomes observed over a nine-month period after a single treatment with 48mg dose of EP-104GI is a promising finding in the treatment of EoE with an injectable delivery system. We believe these results provide further evidence of the precision and durability of our DiffuSphere™ technology and provide a strong foundation as we advance into higher-dose cohorts in the coming quarters.” https://finance.yahoo.com/news/eupraxia-pharmaceuticals-reports-first-quarter-220000192.html

0 · Reply

sprintingtrader May. 16 at 4:30 PM

$EPRX The DiffuSphere opportunity across indications (cancer, arthritis, etc.) is so huge that EPRX does itself a great disservice by focusing outbound comms so much on EOE -- which very few people have even heard of. Don't get me wrong -- I'm all for using EOE as a "proof of concept." You have to start somewhere. But leaving the impression that they're just an EOE company stands between them and maybe a 10x boost to valuation. After their call about recent P2 data, analysts were asking about the minutiae of the P3 trial. If professionals felt that how many sites are enrolled for P3 can move the needle for this stock ... clearly the bigger picture is being missed. And having a webinar whose title is 100% about EOE is an example of why. Management needs to clean up its comms game. They're paying various IR consultants to get their message out -- but the wrong message. IMO, they should change their name to DiffuSphere to highlight being about every application of the tech and NOT just EOE!

0 · Reply

jheerdink May. 13 at 5:29 PM

$EPRX Join the upcoming Tribe Public CEO Presentation and Q&A Webinar event titled "Hard To Swallow: An Underdiagnosed Rising To Surface (EOE)" featuring James A. Helliwell M.D., CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX). This event will take place tomorrow, Wednesday, May 14 at 8:30 am PT/ 11:30 am ET. Register now at EPRX-EOE.TribePublic.com to secure your spot. James A. Helliwell M.D., a board-certified Cardiac Anesthesiologist and the Co-founder and CEO of Eupraxia Pharmaceuticals, will provide a brief presentation and participate in a 5-10 minute Q&A session during this approximately 30-minute event. Don't miss this opportunity to meet and learn from industry leaders, no matter where your day takes you. EOE (Eosinophilic Esophagitis) is an inflammatory disease affecting over 450,000 individuals in the U.S., as reported by Clearview. This condition, characterized by white blood cells accumulating in the esophagus, causes pain and swallowing difficulties.

0 · Reply

Armonica423 May. 10 at 8:31 PM

$EPRX Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research

0 · Reply

jheerdink May. 6 at 10:05 PM

$EPRX Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of 2026 Company to host webinar to discuss updated data from the RESOLVE trial on May 9th https://eupraxiapharma.com/news/news-details/2025/Eupraxia-Pharmaceuticals-Reports-First-Quarter-2025-Financial-Results/default.aspx

0 · Reply

jheerdink May. 6 at 12:40 AM

$EPRX "Eupraxia continues to observe positive treatment outcomes in its ongoing Phase 1b/2a trial, including for the first time clinical responses measured 9 months after dosing with EP-104GI" https://finance.yahoo.com/news/eupraxia-pharmaceuticals-announces-sustained-positive-110000452.html

0 · Reply

Market Cap	190.57M
Revenue (ttm)	0.00
Net Income (ttm)	-25.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	28,400
Avg Vol	14,886
Day's Range	N/A - N/A
Shares Out	35.96M
Stochastic %K	91%
Beta	0.65
Analysts	Strong Sell
Price Target	$11.25